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Abstract: Growth hormone (GH) secretion is regulated by various hormones or neurotransmitters,
including gamma-aminobutyric acid. The aim of this study was to determine the propofol requirement
in patients with GH-secreting pituitary tumors undergoing transsphenoidal surgery. General
anesthesia was induced in 60 patients with GH-secreting tumors (GH group, n = 30) or nonfunctioning
pituitary tumors (NF group, n= 30) using an effect-site target-controlled intravenous propofol infusion.
The effect-site concentrations were recorded at both a loss of consciousness and a bispectral index
(BIS) of 40, along with the effect-site concentration after extubation, during emergence from the
anesthesia. The effect-site concentration of propofol was higher in the GH group than in the NF
group at a loss of consciousness and a BIS of 40 (4.09 ± 0.81 vs. 3.58 ± 0.67, p = 0.009 and 6.23 ± 1.29
vs. 5.50 ± 1.13, p = 0.025, respectively) and immediately after extubation (1.60 ± 0.27 vs. 1.40 ± 0.41,
p = 0.046). The total doses of propofol and remifentanil during anesthesia were comparable between
the groups (127.56 ± 29.25 vs. 108.64 ± 43.16 µg/kg/min, p = 0.052 and 6.67 ± 2.89 vs. 7.05 ± 1.96
µg/kg/h, p = 0.550, respectively). The propofol requirement for the induction of a loss of consciousness
and the achievement of a BIS of 40 is increased during the induction of general anesthesia in patients
with GH-secreting tumors.
Keywords: propofol; general anesthesia; transsphenoidal surgery; growth hormone-secreting
pituitary tumor
1. Introduction
Growth hormone-secreting pituitary tumors are the most common cause of acromegaly, which is
associated with serious complications, including cardiomyopathy and heart failure. Transsphenoidal
pituitary surgery is the standard surgical treatment for most pituitary tumors [1]. A smooth emergence
from general anesthesia is important after this type of surgery to limit the risk of complications,
such as a cerebrospinal fluid leak [2]. Propofol is known to be better than inhalation agents for
reducing the incidence of agitation and delirium after general anesthesia and is widely used in
transsphenoidal pituitary surgery. Propofol exerts a sedative effect by activating the receptor for
gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous
system [3–5]. The pharmacokinetics of propofol can be altered by various factors, including age, sex,
weight, concomitant medications, and underlying diseases, so it is important to tailor the dose to the
individual patient’s requirements [6].
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It is well known that the secretion of growth hormones from the pituitary gland is regulated
primarily by hormones released from the hypothalamus, i.e., growth hormone-releasing hormone and
growth hormone-inhibiting hormone. The hypothalamic pituitary neuroendocrine axis is controlled
by complex networks of various hormones, and hypothalamic GABA can stimulate anterior pituitary
hormone secretion, including that of growth hormones [7–10]. Furthermore, the synthesis of GABA
within the pituitary gland has been reported, which suggests that pituitary GABA has an autocrine
function [11].
We speculated that the interaction between GABA and growth hormones could affect the action
of propofol in patients with acromegaly. The aim of this study was to determine if there is a difference
in the propofol requirement between patients with growth hormone-secreting pituitary tumors and
those with nonfunctioning pituitary tumors.
2. Materials and Methods
The study protocol was approved by the Institutional Review Board of the Yonsei University
Health System, Seoul, South Korea (#4-2017-1241) and is registered at ClinicalTrials.gov (NCT03465423).
Written informed consent was obtained from all patients enrolled in the study, which was conducted
from February 2018 to November 2018. The study population consisted of 60 patients aged over
19 years who underwent elective transsphenoidal pituitary surgery for a nonfunctioning or growth
hormone-secreting tumor. Patients with an abnormal pituitary function, including hypopituitarism,
prolactinoma, Cushing disease, and hypothyroidism were excluded. Patients who had significant
heart disease (e.g., heart failure, arrhythmia, and myocardial infarction), renal disease, suffered a
recent stroke, a psychiatric illness, a cognitive disorder, a propofol allergy, or who were pregnant were
also excluded.
On arrival in the operating room, a bispectral index (BIS) monitor (BIS VISTA Monitoring System,
Aspect Medical Systems Inc., Norwood, MA, USA) was applied to assess the depth of the anesthesia.
Standard intraoperative monitoring, including pulse oximetry, noninvasive blood pressure monitoring,
and electrocardiography, was performed in all cases. All patients were premedicated with 0.2 mg
glycopyrrolate (Glycopyrrolate; Reyon pharm Co., Seoul, Korea). Total intravenous general anesthesia
was induced using an effect-site target-controlled infusion pump (Orchestra Base Primea; Fresenius
Vial, Brézins, France). Propofol (Fresofol MCT 2%; Fresenius Kabi, Seoul, Korea) was administered
according to the Marsh model and remifentanil (Ultian; Hanlim pharm Co., Seoul, Korea) according to
the Minto model [12–14]. The initial target effect-site concentrations (Ces) for propofol and remifentanil
were 3 µg/mL and 3 ng/mL, respectively. The level of consciousness was assessed using a modification
of the Observer Assessment of Awareness and Sedation Scale (OAA/S). When the patient did not
respond to loud and repeated verbal commands (OAA/S score < 2, i.e., indicating a loss of consciousness
(LOC)), rocuronium 0.8 mg/kg was administered. We steadily increased the target Ce of propofol by
increments of 0.5 µg/mL, while maintaining the Ce of remifentanil at 3 ng/mL, until the BIS value
reached 40. The Ce of propofol was recorded at both a LOC and a BIS of 40. The durations from the
start of the propofol administration to LOC and BIS of 40 were also recorded. After tracheal intubation,
the Ce of propofol was adjusted to maintain a BIS value in the range of 40–60. Arterial blood pressure
was monitored via a radial artery catheter and mechanical ventilation was maintained with 50%
oxygen. End-tidal CO2 and esophageal temperature were maintained in the ranges of 35–40 mmHg
and 36–37 ◦C, respectively.
The BIS score was recorded during the emergence phase before the discontinuation of propofol
and remifentanil. The Ce of propofol was recorded when the patients opened their eyes to verbal
command and immediately after extubation. The interval between the discontinuation of propofol and
extubation was also recorded.
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Statistical Analysis
The standard deviation of the Ce of propofol at a LOC in patients undergoing neurosurgery
has been reported to be 0.35 µg/mL [15]. Assuming a between-group difference > 0.3 µg/mL to be
statistically significant, we calculated that 62 patients would need to be enrolled for a power of 0.8.
The descriptive data are presented as the mean ± standard deviation. For between-group
comparisons, either the chi-square test or the Fisher’s exact test was used for categorical variables
and either the Student’s t-test or the Wilcoxon–Mann–Whitney test was used for continuous variables.
All statistical analyses were performed using SPSS Statistics for Windows (version 23; IBM Corp.,
Armonk, NY, USA).
3. Results
Two of the 62 patients deemed eligible for this study declined to participate. Therefore, 60 patients
with growth hormone-secreting tumors (GH group, n = 30) or nonfunctioning tumors (NF group,
n = 30) were finally enrolled. The patient height, weight, and body mass index were higher in the
GH group than in the NF group because of the characteristics of these tumors. Otherwise, there were
no significant between-group differences in the clinical data, including for the duration of anesthesia,
tumor size, sinus invasion of the tumor, intraoperative fluid requirement, bleeding, and urine output
(Table 1).
Table 1. Patient demographics and clinical data in this study.
Nonfunctioning Tumor
(n = 30)
GH-Secreting Tumor
(n = 30) p-Value
Age (year) 50.47 ± 11.79 44.53 ± 12.15 0.060
Sex (male/female) 19/11 22/8 0.405
Height (cm) 164.86 ± 9.58 170.10 ± 11.63 0.027 *
Weight (kg) 67.42 ± 10.92 78.04 ± 16.42 0.005 *
BMI 24.69 ± 2.45 26.40 ± 3.19 0.023 *
ASA (1/2/3) 15/12/3 0/24/6 <0.001 *
Duration of surgery (min) 168.65 ± 58.29 170.58 ± 70.58 0.919
Duration of anesthesia (min) 261.03 ± 65.99 247.83 ± 76.34 0.477
Tumor size (>1 cm) 29 (96.7%) 24 (80%) 0.103
Sinus invasion 11 (36.7%) 7 (23.3%) 0.260
Fluid intake (mL) 1525.00 ± 601.40 1735.67 ± 665.94 0.204
Bleeding (mL) 225.67 ± 147.41 321.67 ± 288.18 0.110
Urine output (mL) 443.67 ± 257.81 438.33 ± 344.93 0.946
Total propofol dose (µg/kg/min) 108.64 ± 43.16 127.56 ± 29.25 0.052
Total remifentanil dose (µg/kg/h) 7.05 ± 1.96 6.67 ± 2.89 0.550
Data are presented as mean ± SD for continuous variables and count (percentage) for categorical variables.
GH: growth hormone. * p < 0.05 compared with nonfunctioning tumor group. ASA, American Society of
Anesthesiologists physical status classification; BMI, body mass index; SD, standard deviation.
During the induction of anesthesia, the Ce of propofol at the time of LOC was higher in the
GH group than in the NF group (4.09 ± 0.81 vs. 3.58 ± 0.67; p = 0.009). The Ce of propofol at a BIS
of 40 was also higher in the GH group than in the NF group (6.23 ± 1.29 vs. 5.50 ± 1.13; p = 0.025;
Table 2). The intervals between the start of the administration of propofol to LOC and BIS of 40 were
comparable between the two groups (2.25 ± 0.94 min vs. 1.83 ± 0.82 min; p = 0.070, 5.42 ± 2.30 min vs.
4.65 ± 1.72 min; p = 0.151).
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Table 2. Comparison of propofol effect-site concentrations between the nonfunctioning tumor patients
and the growth hormone-secreting tumor patients.
Nonfunctioning
Tumor (n = 30)
GH-Secreting
Tumor (n = 30) p-Value
at LOC Ce (µg/mL) 3.58 ± 0.67 4.09 ± 0.81 0.009 *
Time from start of propofol to
LOC (min) 1.83 ± 0.82 2.25 ± 0.94 0.070
BIS 76.57 ± 11.04 75.50 ± 9.18 0.686
at BIS 40 Ce (µg/mL) 5.50 ± 1.13 6.23 ± 1.29 0.025 *
Time from start of propofol to
BIS 40 (min) 4.65 ± 1.72 5.42 ± 2.30 0.151
Immediately after
the extubation Ce (µg/mL) 1.40 ± 0.41 1.60 ± 0.27 0.046 *
Time from discontinuation of
propofol to extubation (min) 15.63 ± 4.18 14.69 ± 3.99 0.380
BIS 79.53 ± 7.92 70.41 ± 19.76 0.026 *
Data are presented as mean ± SD. BIS: bispectral index; Ce: effect-site concentration; GH: growth hormone; LOC:
loss of consciousness. * p < 0.05 compared with nonfunctioning tumor group.
During emergence from the anesthesia, the Ce of propofol was higher in the GH group than in the
NF group immediately after extubation (1.60 ± 0.27 vs. 1.40 ± 0.41, p = 0.046). The BIS value at the time
of extubation was lower in the GH group than in the NF group (70.41 ± 19.76 vs. 79.53 ± 7.92, p = 0.026).
However, the mean Ce of propofol when the patients were able to respond to verbal commands was
comparable between the two groups (1.62 ± 0.28 vs. 1.44 ± 0.44, p = 0.089).
The total dose of propofol during anesthesia was comparable between the two groups
(127.56 ± 29.25 µg/kg/min vs. 108.64 ± 43.16 µg/kg/min; p = 0.052). The total dose of remifentanil was
also comparable between the two groups (6.67 ± 2.89 µg/kg/h vs. 7.05 ± 1.96 µg/kg/h; p = 0.550).
4. Discussion
This study has demonstrated that the propofol requirement for a LOC and the achievement of a
BIS of 40 is higher in patients undergoing transsphenoidal surgery for a growth hormone-secreting
pituitary tumor than in their counterparts with a nonfunctioning pituitary tumor. The Ce of propofol
at the time of a LOC and a BIS of 40 was significantly higher in the GH group than in the NF group.
These findings are clinically significant, because they show that a higher dose of propofol is
required to achieve an adequate depth of anesthesia during the induction and maintenance of the total
intravenous general anesthesia in these patients. It is also noteworthy that extubation was performed
at a higher concentration of propofol and at a higher BIS value in the GH group than in the NF
group. A smooth emergence from anesthesia is essential in patients undergoing transsphenoidal
surgery to avoid complications, such as cerebrospinal fluid leak [2]. Accordingly, the recognition
of the high propofol requirement in these patients would be important for patient safety. Previous
studies of the management of general anesthesia in patients with acromegaly have focused mainly on
airway difficulties and coexisting disease, including cardiac complications [16–18]. To our knowledge,
there have been no reports on the optimal propofol dose for an adequate depth of anesthesia, and this
is the first study to demonstrate an increased propofol requirement in this population.
The mechanism of the action of propofol is not fully understood but is well known to be related to
the potentiation of the gamma-aminobutyric acid A (GABAA) receptor [3,4,19]. The GABAA receptor
is a pentamer composed mostly of three subunits (α, β, and γ). Although there are numerous isoforms
of the GABAA receptor as a result of the various combinations of the subunits, the β subunit plays a
major role in the action of propofol [3,20]. Propofol binds to the GABA receptor and reduces neuronal
excitability by increasing the Cl− current induced by GABA. In high concentrations, propofol can also
directly activate the GABAA receptor [21]. GABA stimulates the secretion of growth hormones via
pituitary GABA receptors and is one of the most important inhibitory neurotransmitters in the central
nervous system [11]. The activity of GABA in patients with acromegaly may be different from that
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in the normal population and may interfere with the action of propofol. However, the mechanism
by which the propofol requirement in patients with growth hormone-secreting tumors is increased
is unclear.
Pituitary GABA is known to be synthesized in the hypothalamus and secreted into the pituitary
gland via the hypophyseal portal vessels [22]. GABAA receptors are distributed in the endocrine
cells in the anterior of the pituitary gland. The synthesis and secretion of GABA also occur in the
pituitary gland itself, implying that GABA acts in an autocrine or paracrine fashion in this gland [11].
When GABA or its agonists bind to the GABAA receptor simultaneously, their effects may be altered
by their interaction, which relates to the location of the subunits to which each agonist binds [23].
The effect of propofol is also affected by the locations of the GABAA receptor on the cell surface [21].
GABAA receptors are located mainly on the postsynaptic membrane; however, extrajunctional GABAA
receptors are also suggested to be important targets for sedative agents [24]. The extrajunctional
GABAA receptors, in particular, have been implicated in the action of propofol [25]. The response of
the GABAA receptors to sedative agents may be altered when they are activated. According to one
study, the action of propofol on extrajunctional GABAA receptors is only effective when the ambient
concentration of GABA is low [26]. The extrajunctional GABAA receptor is likely to be more sensitive
to sedative agents in conditions of low GABA occupancy [24]. Considering the role of GABA as an
important stimulator of growth hormone secretion, the concentration of ambient GABA in patients
with acromegaly may be higher than that in the normal population, and this could be one of the reasons
for the increased propofol requirement in this population.
This study has some limitations. First, we did not measure the plasma concentrations of propofol
in our patients and used the Marsh model to determine its effect-site concentration. However,
the pharmacokinetics in patients with a growth hormone-secreting tumor may still be different from
those in patients with a nonfunctioning tumor and those in the normal population. To our knowledge,
there have been no studies on the pharmacokinetics of propofol in patients with acromegaly, and further
investigations are needed. Second, the height, weight, and body mass index of the patients were not
comparable between the two groups due to the characteristics of these tumors. However, propofol
was administered according to the Marsh model, in which the dose was adjusted based on height and
weight. Thirdly, the study was underpowered in terms of the total dose of propofol administered
during anesthesia, which was one of the secondary outcomes in our study. The actual power of the total
propofol dose in this study was 0.78. Therefore, the total propofol dose during the anesthesia in the GH
group was higher than that in the NF group; however, the difference was not statistically significant.
5. Conclusions
The propofol requirement for a LOC and the achievement of a BIS of 40 are increased during the
induction of general anesthesia in patients with a growth hormone-secreting tumor, meaning that
a higher dose of propofol is needed to achieve an adequate depth of anesthesia in this population.
Further studies elucidating the underlying mechanism are warranted.
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